Schizophrenia
📧 Sign up to get email alerts when something new happens for Schizophrenia.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2021-11-12FDA Approved: HALOPERIDOL DECANOATE — Supplemental Application (Somerset Therapeutics, LLC)
FDA approved a supplemental application for HALOPERIDOL DECANOATE submitted by Somerset Therapeutics, LLC.
-
FDA approval · 2021-11-10FDA Approved: CLOZAPINE — Supplemental Application (Mylan Pharmaceuticals Inc.)
FDA approved a supplemental application for Clozapine from Mylan Pharmaceuticals Inc., expanding its approved labeling and indications.
-
FDA approval · 2021-11-10FDA Approved: CLOZARIL — Supplemental Application (HLS Therapeutics (USA), Inc.)
FDA approved a supplemental application for CLOZARIL (clozapine) submitted by HLS Therapeutics (USA), Inc.
-
FDA approval · 2021-11-10FDA Approved: CLOZAPINE — Supplemental Application (Accord Healthcare Inc.)
FDA approved Accord Healthcare Inc.'s Supplemental Application for CLOZAPINE, a generic version of clozapine under ANDA 202873. The approval…
-
FDA approval · 2021-11-10FDA Approved: CLOZAPINE — Supplemental Application (Teva Pharmaceuticals USA, Inc.)
FDA approved Teva's supplemental application for Clozapine (generic) under ANDA090308. This constitutes an approved supplemental modificatio…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2021-11-10FDA Approved: CLOZAPINE — Supplemental Application (Aurobindo Pharma Limited)
FDA approved a supplemental application for Clozapine from Aurobindo Pharma Limited, enabling a generic version to proceed.
-
FDA label_change · 2021-11-10FDA Approved: VERSACLOZ — Supplemental Application (TruPharma LLC)
The FDA approved a supplemental application for VERSACLOZ (clozapine) submitted by TruPharma LLC.
-
FDA approval · 2021-11-10FDA Approved: CLOZAPINE — Supplemental Application (Mylan Pharmaceuticals Inc.)
FDA approves Mylan's supplemental application for Clozapine, allowing a generic version of Clozapine to be marketed.
-
FDA approval · 2021-11-09FDA Approved: QUETIAPINE FUMARATE — Supplemental Application (Macleods Pharmaceuticals Limited)
The FDA approved a supplemental application for quetiapine fumarate from Macleods Pharmaceuticals Limited, enabling a generic version of the…
-
FDA approval · 2021-11-03FDA Approved: OLANZAPINE — Supplemental Application (Aurobindo Pharma Limited)
The FDA approved a supplemental application for olanzapine from Aurobindo Pharma Limited under ANDA 203708, finalizing approval of a generic…
-
FDA approval · 2021-11-02FDA Approved: ZIPRASIDONE — Supplemental Application (Dr. Reddy's Laboratories Limited)
FDA approves a supplemental application for ZIPRASIDONE from Dr. Reddy's Laboratories Limited, indicating the approval of a generic version …
-
FDA approval · 2021-11-02FDA Approved: QUETIAPINE FUMARATE — Supplemental Application (Unichem Pharmaceuticals (USA), Inc.)
FDA approved a supplemental application for Quetiapine Fumarate from Unichem Pharmaceuticals (USA), Inc. The action approves changes to the …
-
CLINICAL_TRIALS trial_result · 2021-11-02Clinical Trial Update: ITI-007 (Lumateperone Tosylate) for Schizophrenia [Phase 2]
Phase 2 trial of ITI-007 (Lumateperone Tosylate) for schizophrenia has been terminated with results posted in 2021.
-
FDA approval · 2021-11-01FDA Approved: QUETIAPINE FUMARATE — Supplemental Application (Aurobindo Pharma Limited)
The FDA approved a supplemental application for a generic quetiapine fumarate product from Aurobindo Pharma Limited, enabling its use as a g…
-
CLINICAL_TRIALS trial_result · 2021-10-26Clinical Trial Update: An Integrated Program for the Treatment of First Episode of Psychosis [NA]
Clinical trial update documenting completion of an integrated program for first-episode psychosis, with results posted.
-
FDA approval · 2021-10-25FDA Approved: LURASIDONE HYDROCHLORIDE — Supplemental Application (Heritage Pharma Labs Inc. d/b/a Avet Pharmaceuticals Inc.)
FDA approves a supplemental application for lurasidone hydrochloride by Heritage Pharma Labs (Avet) under an ANDA, enabling continued or exp…
-
CLINICAL_TRIALS trial_result · 2021-10-22Clinical Trial Update: Naltrexone and Bupropion Combination on Obese,Smoking Patients With Schizophrenia [Phase 4]
Phase 4 trial evaluating a naltrexone and bupropion combination in obese, cigarette-smoking individuals with schizophrenia has completed wit…
-
CLINICAL_TRIALS trial_result · 2021-10-21Clinical Trial Update: Minocycline and Tobacco Craving in Smokers With Schizophrenia [Phase 4]
Phase 4 trial assessing minocycline for tobacco craving in smokers with schizophrenia; study completed with results posted.
-
FDA approval · 2021-10-20FDA Approved: FLUPHENAZINE HYDROCHLORIDE — Original Application (Zameer Pharmaceuticals LLC)
FDA approved the original ANDA for fluphenazine hydrochloride (generic) manufactured by Zameer Pharmaceuticals LLC.
-
CLINICAL_TRIALS trial_result · 2021-10-12Clinical Trial Update: Reducing the Burden of Chronic Psychotic Disorders in Tanzania (CAPACITY) [Phase 3]
Phase 3 clinical trial updating the burden of chronic psychotic disorders in Tanzania (CAPACITY) completed with results posted.
-
CLINICAL_TRIALS trial_result · 2021-10-11Clinical Trial Update: Pentoxifylline Add-on Therapy for Schizophrenia [Phase 1, Phase 2]
Clinical trial update describes pentoxifylline as add-on therapy for schizophrenia in Phase 1 and Phase 2 studies.
-
CLINICAL_TRIALS trial_result · 2021-10-08Clinical Trial Update: A Study of ALKS 3831 in Subjects With Schizophrenia and Alcohol Use Disorder [Phase 2]
Phase 2 study of ALKS 3831 in adults with schizophrenia and alcohol use disorder has completed and results posted.
-
CLINICAL_TRIALS trial_result · 2021-10-08Clinical Trial Update: Raloxifene Augmentation in Patients With a Schizophrenia Spectrum Disorder [Phase 3]
Phase 3 clinical trial evaluating raloxifene augmentation in patients with schizophrenia-spectrum disorders has completed.
-
CLINICAL_TRIALS trial_result · 2021-10-08Clinical Trial Update: Study of the Effect of Dosing on Clozapine Levels [Phase 4]
Phase 4 trial investigating how dosing impacts clozapine levels was withdrawn.
-
FDA approval · 2021-09-28FDA Approved: PROCHLORPERAZINE EDISYLATE — Original Application (Cosette Pharmaceuticals, Inc.)
FDA approves Cosette Pharmaceuticals' prochlorperazine edisylate as an original generic application for use as an antiemetic.